SHR-3836
/ Jiangsu Hengrui Pharma
- LARVOL DELTA
Home
Next
Prev
1 to 1
Of
1
Go to page
1
June 05, 2026
A Phase I Study of SHR-3836 in Patients With Multiple Myeloma
(clinicaltrials.gov)
- P1 | N=99 | Recruiting | Sponsor: Shanghai Hengrui Pharmaceutical Co., Ltd. | Not yet recruiting ➔ Recruiting
Enrollment open • Hematological Malignancies • Multiple Myeloma • Oncology
1 to 1
Of
1
Go to page
1